m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05737
 [1]
m6A modification hsa-miR-99a-5p hsa-miR-99a-5p METTL3 Methylation : m6A sites Direct Enhancement Non-coding RNA miR-99a-5p BTRCP1  lncRNA       miRNA   circRNA
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target hsa-miR-99a-5p
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator hsa-miR-99a-5p microRNA View Details
Regulated Target Beta-transducin repeat containing E3 ubiquitin protein ligase pseudogene 1 (BTRCP1) View Details
Crosstalk Relationship m6A  →  ncRNA Enhancement
Crosstalk Mechanism m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA
Crosstalk Summary METTL3-Mediated Maturation of hsa-miR-99a-5p Promotes Cell Migration and Invasion in Oral Squamous Cell Carcinoma by Targeting Beta-transducin repeat containing E3 ubiquitin protein ligase pseudogene 1 (BTRCP1).
Responsed Disease Oral squamous cell carcinoma ICD-11: 2B6E.0
 Disease Info 
Cell Process Cell migration
Cell invasion
In-vitro Model
 HOK Normal Hexagrammos otakii CVCL_YE19
CAL-27 Tongue squamous cell carcinoma Homo sapiens CVCL_1107
SCC-9 Tongue squamous cell carcinoma Homo sapiens CVCL_1685
SCC-15 Tongue squamous cell carcinoma Homo sapiens CVCL_1681
UM2 Tongue squamous cell carcinoma Homo sapiens CVCL_VH01
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2B6E: Head and neck squamous carcinoma 3 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name OraTest Approved [2]
External Link
TTD: D00DCY
 Compound Name Contusugene ladenovec Phase 3 [3]
Synonyms
Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR
    Click to Show/Hide
External Link
TTD: D04FYL
 Compound Name INGN-234 Discontinued in Phase 2 [4]
Synonyms
P53 tumor suppressor (topical formulation), Introgen
    Click to Show/Hide
External Link
TTD: D05AHK
References
Ref 1 METTL3-Mediated Maturation of miR-99a-5p Promotes Cell Migration and Invasion in Oral Squamous Cell Carcinoma by Targeting ZBTB7A. Mol Biotechnol. 2024 Aug;66(8):1942-1953. doi: 10.1007/s12033-023-00815-x. Epub 2023 Jul 27.
Ref 2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 3 ClinicalTrials.gov (NCT00041613) Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate. U.S. National Institutes of Health.
Ref 4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028790)